Christin Destefano
Hematology & Oncology · Bethesda, MDNPI 1124388384
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.4% of the total across 125 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 10.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $909 and has fallen 56.6% since, to $394 in 2025.
Across 125 payments — averaging $25.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$342
- E.r. Squibb & Sons, L.L.C.$238
- Karyopharm Therapeutics Inc.$217
- Incyte Corporation$209
- Sanofi$209
- Mirati Therapeutics, Inc.$163
- plus $2K from 31 others
Across 6 payments — averaging $16,856 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$97K
- Janssen Research & Development, LLC$4K
What the payments were for
- Food & beverage$3,04296%
- Education$1154%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 10 | $342 |
| E.r. Squibb & Sons, L.L.C. | 16 | $238 |
| Karyopharm Therapeutics Inc. | 9 | $217 |
| Incyte Corporation | 6 | $209 |
| Sanofi | 8 | $209 |
| Mirati Therapeutics, Inc. | 3 | $163 |
| AstraZeneca(2 entities) | 8 | $144 |
| Jazz Pharmaceuticals Inc. | 1 | $143 |
| Exelixis Inc. | 5 | $129 |
| Bristol Myers Squibb | 5 | $123 |
| Gilead | 4 | $122 |
| Kyowa Kirin, Inc. | 1 | $122 |
| Merck | 7 | $114 |
| Daiichi Sankyo Inc. | 5 | $99 |
| Morphosys, US Inc. | 3 | $68 |
| Genmab U.S., Inc. | 2 | $66 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $62 |
| Sobi, Inc | 2 | $49 |
| Coherus Oncology, Inc. | 2 | $46 |
| Recordati_rare_diseases_inc. | 2 | $45 |
| AVEO Pharmaceuticals, Inc. | 2 | $43 |
| Amgen | 3 | $39 |
| Boehringer Ingelheim | 2 | $36 |
| Eisai Inc. | 2 | $31 |
| Genentech USA, Inc. | 2 | $29 |
| Seagen Inc. | 2 | $29 |
| Alnylam Pharmaceuticals Inc. | 1 | $28 |
| Tersera Therapeutics LLC | 1 | $26 |
| GSK | 1 | $25 |
| ADC Therapeutics America, Inc. | 1 | $24 |
| Immunogen, Inc. | 1 | $23 |
| Rigel Pharmaceuticals, Inc. | 1 | $23 |
| Beone Medicines USA, Inc. | 1 | $22 |
| BTG International Inc. | 1 | $19 |
| Tesaro, Inc. | 1 | $19 |
| Clovis Oncology, Inc. | 1 | $17 |
| AMAG Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,157 in reported general payments places this provider in the 55th percentile of 242 hematology & oncology providers in Maryland.
Other hematology & oncology in Bethesda
- Ralph BocciaBethesda$3.1M
- Sandra SwainBethesda$1M
- Chitra RajagopalBethesda$89K
- Susan LeitmanBethesda$44K
- Giuseppe GiacconeBethesda$32K
- Phillip ScheinbergBethesda$27K
- Steven PavleticBethesda$13K
- Kashif AliSilver Spring$987K
- Ani BalmanoukianBaltimore$842K
- Benjamin LevyBaltimore$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.